R Leibowitz-Amit
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25:657-62.
23.01.2014Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
23.01.2014Ann Oncol 2014; 25:657-62
Leibowitz-Amit R, de Bono J S, Tannock I F, Sridhar S S, Knox J J, Attard G, Seah J-A, Vera-Badillo F, Keizman D, Atenafu E G, Pezaro C, Omlin Aurelius, Templeton Arnoud, Joshua A M
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
Templeton A, Amir E, Pond G, Joshua A, Sridhar S, Moore M, Knox J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F, Tannock I. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24:2972-7.
14.10.2013Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
14.10.2013Ann Oncol 2013; 24:2972-7
Templeton Arnoud, Amir E, Pond G R, Joshua A M, Sridhar S S, Moore M, Knox J J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F E, Tannock I F